Search Results

You are looking at 11 - 20 of 27 items for :

  • "suboptimal response" x
  • User-accessible content x
Clear All
Full access

Jerald P. Radich, Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori Maness, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory and Hema Sundar

Sokal risk score, female sex, lower natural killer cell counts, suboptimal response or resistance to imatinib, duration of TKI therapy, and deep molecular response prior to TKI discontinuation). 149 , 150 , 156 – 160 , 162 However, only the duration of

Full access

Elias Jabbour, Michael S. Mathisen and Susan O’Brien

, once daily. 21 Patients with suboptimal response could have the imatinib dose increased. The primary end point was MMR at 12 months, which was achieved in more patients in the nilotinib arms than in the imatinib arm (44% and 43% vs. 22%; P < .001

Full access

Jerald P. Radich, Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, Jane Houldsworth, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Meir Wetzler and Jane N. Winter

E . European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor . Blood 2008 ; 112 : 4437 – 4444 . 42 Kantarjian HM

Full access

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar

suboptimal response or disease progression (in 67% of patients). Six additional patients experienced a PR after addition of dexamethasone. 28 The ORR (PR or better) with or without the addition of dexamethasone was 34%. 28 Adverse events of grade 3 or

Full access

Susan O’Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Javier Pinilla-Ibarz, Vishnu VB. Reddy, Neil P. Shah, B. Douglas Smith, David S. Snyder, Meir Wetzler, Kristina Gregory and Hema Sundar

transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib . Haematologica 2010 ; 95 : 232 – 240 . 7. Shah NP Kantarjian H Kim DW . Six-year (yr) follow

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson and Paul G. Richardson

dexamethasone added for suboptimal response after 3 cycles. 70 The bortezomib, thalidomide, and dexamethasone combination yielded an overall response rate (minimal response or better) of 79%, a partial response rate of 63%, and an nCR rate of 22%. The 4-year

Full access

Cesar A. Santa-Maria and Rita Nanda

control arm received carboplatin in addition to chemotherapy if they were found to have a suboptimal response to standard chemotherapy. Even if these patients went on to achieve a pCR, for the purposes of the study, they were counted as non-pCR because

Full access

Michael W. Deininger, Neil P. Shah, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Lori Maness, Monica Mead, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Kiran Naqvi, Vivian Oehler, Arnel M. Pallera, Mrinal Patnaik, Keith Pratz, Iskra Pusic, Michal G. Rose, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory and Hema Sundar

to imatinib was associated with poorer response. Patients with suboptimal response missed significantly more imatinib doses (23%) than did those with optimal response (7%). 155 Adherence to imatinib therapy has been identified as the only independent

Full access

William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer and Hema Sundar

. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy . Blood 2014 ; 123 : 1810 – 1817 . 55. Brown JR Byrd JC Coutre SE . Idelalisib, an

Full access

Stephen Harnicar

suboptimal response were less likely to adhere to imatinib. 33 Although no clinical data support routine measurement of imatinib plasma levels, this may be useful in determining patient adherence. Secondary resistance (also known as acquired resistance ) is